| 摘要 |
Background: Congenital obstructing posterior urethral membrane (COPUM) or posterior urethral valve (PUV) is the most common cause of lower urinary tract obstruction in boys. Approximately one‑third of boys with PUV develop end‑stage renal disease. Various prognostic factors have been recognized which determines
the long‑term outcome of these cases.
Materials and Methods: This was a retrospective case–control analysis of data from January 1998 to May 2014. All patients of COPUM with radiological evidence of bladder neck hypertrophy with follow‑up of 7 years were included in the study. Patients with urethral strictures, neurogenic bladder, and incomplete
records were excluded. Group I (n = 57) received selective α‑1 blocker (prazosin), after valve ablation. Group II (n = 36) who had not received the α‑1 blocker was treated as a control group. Investigations include renal function test, ultrasonography, micturating cystourethrography renal dynamic scan, and glomerular filtration rate. Statistical analysis was done using the paired t‑test, multiple serial analyses using ANOVA. P <0.05 was considered as significant.
Results: A total of 113 patients of COPUM were treated from January 1998 to May 2014. Out of these 113, 93 patients (82.3%) were included in the study. Fifty‑seven (61.2%) received α‑1 blocker, while 36 patients (38.8%) acted as control. Significant decrease in bladder neck hypertrophy noted in Group I as
compared to Group II (P<0.001).
Conclusion: Uses of alpha‑1 blocker hastens the recovery in terms of clinical improvement, resolution of bladder neck hypertrophy, and improved peak urine flow rate. |
